MD An­der­son­'s Patrick Hwu to helm Mof­fitt Can­cer Cen­ter; Af­ter Rock­well Med­ical ouster, Robert Chioi­ni gets an­oth­er chance to lead

Patrick Hwu

→ The Mof­fitt Can­cer Cen­ter in Tam­pa has found its next pres­i­dent and CEO af­ter the im­broglio sur­round­ing the de­par­ture of Alan List.

Patrick Hwu, the head of can­cer med­i­cine at MD An­der­son Can­cer Cen­ter, has been tapped to lead Mof­fitt al­most ex­act­ly 8 months fol­low­ing the mass res­ig­na­tions of List, cen­ter di­rec­tor Thomas Sell­ers and 4 oth­er re­searchers for con­flict of in­ter­est re­gard­ing their work in Chi­na, one of sev­er­al high-pro­file ex­am­ples that in­clude Har­vard pro­fes­sor Charles Lieber.

Hwu, who of­fi­cial­ly starts Nov. 10, spent 17 of his 33 years in on­col­o­gy at MD An­der­son in promi­nent lead­er­ship po­si­tions. Be­sides his most re­cent role, he chaired the De­part­ment of Sar­co­ma Med­ical On­col­o­gy and was the first chair of the De­part­ment of Melanoma Med­ical On­col­o­gy. Hwu was al­so co-di­rec­tor of the Cen­ter for Can­cer Im­munol­o­gy Re­search.

“I’m con­fi­dent that our col­lec­tive ef­forts will fur­ther el­e­vate Mof­fitt’s lead­er­ship in can­cer pa­tient care, re­search and ed­u­ca­tion,” Hwu said in a state­ment.

Robert Chioi­ni

Robert Chioi­ni made head­lines back in 2018 when he at­tempt­ed to un­fire him­self as CEO of Rock­well Med­ical, as­sert­ing that those who vot­ed against him vi­o­lat­ed fed­er­al se­cu­ri­ties laws. With that messy dis­missal be­hind him fol­low­ing a set­tle­ment deal, Chioi­ni is back in the sad­dle, tak­ing over as CEO of Toron­to life sci­ences com­pa­ny SQI Di­ag­nos­tics. Er­ic Brouw­er has sub­se­quent­ly stepped aside as in­ter­im CEO, but he will con­tin­ue on as CSO at SQI.

“I look for­ward to work­ing with the team to un­lock the po­ten­tial across our suite of clin­i­cal and point of care di­ag­nos­tic prod­ucts,” Choi­ni, who found­ed Rock­well Med­ical in 1995, said in a state­ment. “Now more than ever, we see the im­por­tance of ac­cu­rate, wide­ly avail­able, and rapid di­ag­nos­tic tests.”

Ravi Rao

→ Start­ing Sept. 1, So­bi is bring­ing in Ravi Rao as head of R&D af­ter the EMA spurned the Stock­holm phar­ma’s pitch for ema­palum­ab (which has al­ready been ap­proved in the US) in late Ju­ly. Be­fore link­ing up with Stock­holm-based So­bi, which fo­cus­es on hema­tol­ogy and im­munol­o­gy, Rao wrapped up a run as CMO of Ae­glea Bio­ther­a­peu­tics. His Big Phar­ma ex­pe­ri­ence ranges from his 5 years at Roche, where he was group med­ical di­rec­tor, im­munol­o­gy clin­i­cal de­vel­op­ment, to 7 years as a VP at GSK, where he led the im­munol­o­gy and spe­cial­ty med­i­cine fran­chise up­on his de­par­ture to Ae­glea.

James Hussey has been around the block ei­ther as a pres­i­dent or CEO, and now he’s at the helm of Seneca Ther­a­peu­tics, look­ing to push its on­colyt­ic virus SVV-001 in­to clin­i­cal tri­als some­time in 2021. Hussey, who got his ca­reer go­ing at Bris­tol My­ers in the 1980s, has been the CEO of NeoPharm and NanoInk as well as the pres­i­dent of Sagent Phar­ma­ceu­ti­cals. Among his most re­cent roles, Hussey has been act­ing US pres­i­dent of Mor­phoSys and EVP of Athenex.

Kristof Ver­cruysse

Per­somed, a Bel­gian con­sor­tium look­ing to scale up de­vel­op­ment of per­son­al­ized can­cer vac­cines, has named Abl­ynx vet Kristof Ver­cruysse as their CEO. Most re­cent­ly he has been the chief de­vel­op­ment of­fi­cer and CMO at TargED Bio­phar­ma­ceu­ti­cals, for­mer­ly known as IO­VA. Ver­cruysse was di­rec­tor of clin­i­cal op­er­a­tions at Abl­ynx from 2007-13.

Matt Brokaw has been cho­sen to take the helm as pres­i­dent and CEO of med­ical de­vice com­pa­ny Aerin Med­ical, which aims to pro­vide non-in­va­sive pro­ce­dures for treat­ing chron­ic nasal air­way con­di­tions. Brokaw has pre­vi­ous­ly held lead­er­ship po­si­tions in mar­ket­ing at com­pa­nies with ENT port­fo­lios, such as Smith+Nephew (which just ac­quired Tusker Med­ical in Jan­u­ary) and Stryk­er. Along with Brokaw’s ap­point­ment, Aerin Med­ical al­so re­vealed the close of their $48 mil­lion eq­ui­ty fi­nanc­ing.

→ Fo­cused on the re­peatome in drug de­vel­op­ment, ROME Ther­a­peu­tics has brought on Den­nis Za­ller to be their CSO. A for­mer ex­ec­u­tive di­rec­tor at Mer­ck and Cel­gene/BMS, Za­ller has col­lab­o­rat­ed in the past with ROME’s pres­i­dent, CEO and co-founder, Rosana Kapeller. On Wednes­day our Max Gel­man spoke with Za­ller and Kapeller, which you can read here.

→ Long­time phar­ma ex­ec Paul Ko­rner is head­ed to Prince­ton, NJ women’s health­care com­pa­ny Ag­ile Ther­a­peu­tics as their CMO. Ko­rner has held a va­ri­ety of ex­ec­u­tive ti­tles, in­clud­ing SVP of US de­vel­op­ment at Fer­ring Phar­ma­ceu­ti­cals, which has made women’s health one of its ar­eas of fo­cus. He just com­plet­ed a more than year-and-a-half run as Ax­o­vant’s SVP, clin­i­cal de­vel­op­ment & med­ical af­fairs, and from 2005-08, Ko­rner was Bay­er’s VP of med­ical af­fairs, women’s health.

Al­ka Chaubey

Al­ka Chaubey has made her way to San Diego-based gene se­quenc­ing play­er Bio­nano Ge­nomics as their first CMO. A well-known fig­ure through­out the mol­e­c­u­lar di­ag­nos­tics and cy­to­ge­net­ics com­mu­ni­ties, Chaubey is cur­rent­ly the head of cy­toge­nomics for PerkinElmer Ge­nomics, and she al­so spent 10 years at South Car­oli­na’s Green­wood Ge­net­ic Cen­ter, in­clud­ing 7 years as their di­rec­tor.

→ Bio­mark­er-dri­ven Ike­na On­col­o­gy has turned to Big Phar­ma vet Ser­gio San­til­lana to be their CMO. San­til­lana al­so led med­ical op­er­a­tions at Mer­ri­mack Phar­ma­ceu­ti­cals and ARI­AD Phar­ma­ceu­ti­cals pri­or to join­ing Boston-based Ike­na. He’s al­so held a num­ber of on­col­o­gy clin­i­cal de­vel­op­ment lead­er­ship roles at Eli Lil­ly (2002-06), GSK (2006-14) and Take­da (2014-16), where he was their se­nior med­ical di­rec­tor, on­col­o­gy clin­i­cal re­search.

Yasir Al-Wa­keel

Nor­bert Bischof­berg­er has been busy all sum­mer bol­ster­ing his ex­ec­u­tive lead­er­ship at Kro­nos Bio, and this week is no dif­fer­ent as Yasir Al-Wa­keel heads to the biotech as their CFO and head of cor­po­rate de­vel­op­ment af­ter a 3-year run as CFO and head of strat­e­gy at Neon Ther­a­peu­tics. Al-Wa­keel held the same ti­tles at Mer­ri­mack Phar­ma­ceu­ti­cals as he does now at Kro­nos, which gob­bled up two of Gilead’s SYK in­hibitors in Ju­ly. We fea­tured him in our 2018 re­port on the un­der-40 crowd mak­ing a mark in biotech.

→ San Diego im­munother­a­py play­er Fate Ther­a­peu­tics has en­list­ed Cel­gene vet Ed­ward Du­lac as their new CFO. Du­lac start­ed at Cel­gene in 2012 as their di­rec­tor of glob­al mar­ket­ing and rose to VP, busi­ness de­vel­op­ment and strat­e­gy be­fore jump­ing over to Fate, which de­vel­ops off-the-shelf cell prod­ucts with its pro­pri­etary in­duced pluripo­tent stem cell (iP­SC) prod­uct plat­form.

→ British Co­lum­bia-based Xenon Phar­ma­ceu­ti­cals, tar­get­ing neu­ro­log­i­cal dis­or­ders, has tapped Chris Von Seg­gern as chief com­mer­cial of­fi­cer. Dur­ing a tenure of near­ly 12 years at ClearView Health­care Part­ners, most of Von Seg­gern’s en­er­gy was geared to­ward or­phan dis­eases and trans­for­ma­tion­al tech­nolo­gies.

Richard Katz has an­nounced his res­ig­na­tion as CFO at Liq­uidia Tech­nolo­gies, which is look­ing to go toe-to-toe with stan­dard-of-care Ty­va­so in the de­vel­op­ment of their drug LIQ861 for pul­monary ar­te­r­i­al hy­per­ten­sion. Steven Bariahtaris is step­ping in as in­ter­im CFO at the Re­search Tri­an­gle phar­ma un­til the po­si­tion is filled. Bariahtaris was a long­time J&J ex­ec in sev­er­al ca­pac­i­ties, leav­ing the phar­ma gi­ant ear­ly this year as their chief au­dit ex­ec­u­tive. While at J&J, he was al­so their CFO & VP of fi­nance for Janssen Amer­i­c­as.

Ju­lianne Aver­ill

Ju­lianne Aver­ill has tak­en on the CFO post at Bay Area in­fec­tious dis­ease di­ag­nos­tic tech start­up Alveo Tech­nolo­gies, which an­nounced a col­lab­o­ra­tion with Janssen Phar­ma­ceu­ti­cals in April to bring its be.well test­ing sys­tem to mar­ket. A De­loitte vet, Aver­ill hails from Black­Thorn Ther­a­peu­tics, where she was their VP, fi­nance since Jan­u­ary 2019.

→ Rare dis­ease biotech San­i­fit — which raised near­ly $81 mil­lion last June in Spain’s largest-ever pri­vate biotech fundraise — has made the ad­di­tion of Adam Levy as CFO. Most re­cent­ly, Levy served as CBO of Brick­ell Biotech and has pre­vi­ous ex­pe­ri­ence with mi­Ra­gen Ther­a­peu­tics, Mer­rill Lynch and Jef­feries Group among oth­ers.

→ San Diego-based biotech Zai Lab has snapped up Ty Ed­mond­son as chief le­gal of­fi­cer. Ed­mond­son hails from Bio­gen, where he served as SVP, chief cor­po­ra­tion coun­sel and as­sis­tant sec­re­tary. Pri­or to Bio­gen, Ed­mond­son served in roles at Sepra­cor, Sum­it­o­mo Dainip­pon Phar­ma, Ei­sai and Bris­tol My­ers Squibb among oth­ers.

Liz Hen­der­son

Mer­ck KGaA has made Liz Hen­der­son re­gion­al VP of Mer­ck Bio­phar­ma Asia Pa­cif­ic (APAC), based in Sin­ga­pore. A Pfiz­er and Am­gen vet, Hen­der­son has spent the last 18 months in Lon­don as Mer­ck’s man­ag­ing di­rec­tor and GM, Mer­ck UK & Re­pub­lic of Ire­land and has been at Mer­ck since 2009. In her new role, she will cov­er 11 APAC coun­tries across the phar­ma’s 4 ther­a­py ar­eas: on­col­o­gy, fer­til­i­ty, neu­rol­o­gy and im­munol­o­gy, and gen­er­al med­i­cine and en­docrinol­o­gy.

Tyme Tech­nolo­gies — fo­cused on the de­vel­op­ment of can­cer me­tab­o­lism-based ther­a­pies — has named John Roth­man as EVP, prod­uct de­vel­op­ment. Roth­man pre­vi­ous­ly served in roles at Scher­ing-Plough, Roche and Ad­vax­is.

Lori Hoff­man has moved to Prince­ton, NJ-based Slay­back Phar­ma as their head of al­liance man­age­ment af­ter lead­ing Fron­ti­da’s al­liance man­age­ment func­tion the last 3 years. Be­fore Fron­ti­da, Hoff­man spent more than 9 years at Sagent Phar­ma­ceu­ti­cals, the ma­jor­i­ty of which was spent as their se­nior di­rec­tor, busi­ness de­vel­op­ment.

Ted Love

Seat­tle Ge­net­ics has reeled in Glob­al Blood Ther­a­peu­tics pres­i­dent and CEO Ted Love to its board of di­rec­tors. Love brings a wealth of ex­pe­ri­ence from Onyx Phar­ma­ceu­ti­cals, Nu­velo, Ther­a­vance and Genen­tech.

Be­yond­Spring is mak­ing a big splash with the ad­di­tion of Ravin­dra Ma­jeti to its board of di­rec­tors. Ma­jeti co-found­ed Forty Sev­en out of Stan­ford in 2016, be­fore the com­pa­ny was ac­quired by Gilead in a $4.9 bil­lion buy­out. Af­ter snag­ging $123 mil­lion from the deal, Ma­jeti cur­rent­ly serves as chief, di­vi­sion of hema­tol­ogy at Stan­ford Uni­ver­si­ty.

Gar­ry Men­zel

TCR² Ther­a­peu­tics CEO Gar­ry Men­zel has been giv­en a seat on ge­net­ic dis­ease biotech Stoke Ther­a­peu­tics’ board of di­rec­tors. Men­zel is al­so a found­ing di­rec­tor at Black Di­a­mond Ther­a­peu­tics.

Michael Cham­bers has been se­lect­ed to the board of di­rec­tors at Calviri, a can­cer-fo­cused spin­out of the Biode­sign In­sti­tute at Ari­zona State. Cham­bers left his CEO post at Alde­vron but re­mains their chair­man.

Liz Kwo

Flex­ion Ther­a­peu­tics, which struck a deal in April to de­vel­op and com­mer­cial­ize Zil­ret­ta in Chi­na, has brought on Liz Kwo as a mem­ber of their board of di­rec­tors. Kwo is the staff VP, clin­i­cal da­ta an­a­lyt­ics at An­them.

Jakob Dupont, for­mer CMO at Gos­samer Bio, has joined Apex­i­gen‘s board of di­rec­tors. Dupont cur­rent­ly serves as EVP, head of glob­al re­search and de­vel­op­ment at Atara Bio­ther­a­peu­tics and was pre­vi­ous­ly at Genen­tech/Roche and On­coMed Phar­ma­ceu­ti­cals.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.